The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Open accessAbstract
During carcinogenesis of pancreatic islets in transgenic mice, an angiogenic switch activates the quiescent vasculature. Paradoxically, vascular endothelial growth factor (VEGF) and its receptors are expressed constitutively. Nevertheless, a synthetic inhibitor (SU5416) of VEGF signalling impairs angiogenic switching and tumour growth. Two metalloproteinases, MMP-2/gelatinase-A and MMP-9/gelatinase-B, are upregulated in angiogenic lesions. MMP-9 can render normal islets angiogenic, releasing VEGF. MMP inhibitors reduce angiogenic switching, and tumour number and growth, as does genetic ablation of MMP-9. Absence of MMP-2 does not impair induction of angiogenesis, but retards tumour growth, whereas lack of urokinase has no effect. Our results show that MMP-9 is a component of the angiogenic switch.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Genetic and functional experiments indicate that neutrophils, mast cells, eosinophils and activated T lymphocytes also contribute to malignancies by releasing extracellular proteases, pro-angiogenic factors and chemokines11,23–26.”
From Inflammation and cancer (2002) · cites this paper as [26]
In the citing paper
“Furthermore, the actions of MMP-9 both break down the fibrous collagen matrix to make space for new blood vessels and release matrix-bound VEGF (53).”
From The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis. (2017) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Self-citationTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Self-citationAbnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,162
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O’Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,661
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Gerber, H. P., Vu, T. H., Ryan, A. M., Kowalski, J., Werb, Z., & Ferrara, N. (1999) · Nature Medicine · doi:10.1038/9467 · Cited by 2,107
Self-citationYu, Q., & Stamenkovic, I. (2000) · PubMed · Cited by 1,952
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Self-citationYu, Q., & Stamenkovic, I. (2000) · Genes & Development · doi:10.1101/gad.14.2.163 · Cited by 1,754
Cited by
Sorted by citations
Items 201–300 of 1,009
The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis
Chang, C., & Werb, Z. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)82222-4 · Cited by 342
Self-citationAdrover, J. M., McDowell, S. A. C., He, X., Quail, D. F., & Egeblad, M. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.001 · Cited by 365
Tang, Y., Nakada, M. T., Kesavan, P., McCabe, F. L., Millar, H. J., Rafferty, P., Bugelski, P. J., & Li, Y. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3605 · Cited by 338
Extracellular matrix, inflammation, and the angiogenic response
Arroyo, A. G., & Iruela‐Arispe, M. L. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq049 · Cited by 353
Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice
Gong, Y., Hart, E., Shchurin, A., & Hoover-Plow, J. L. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32750 · Cited by 334
THE ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN OCULAR HEALTH AND DISEASE
Adamis, A. P., & Shima, D. T. (2005) · Retina · doi:10.1097/00006982-200502000-00001 · Cited by 336
Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression
Shojaei, F., Singh, M., Thompson, J. D., & Ferrara, N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712185105 · Cited by 344
Multifaceted link between cancer and inflammation
Sethi, G., Shanmugam, M. K., Ramachandran, L., Kumar, A. P., & Tergaonkar, V. (2011) · Bioscience Reports · doi:10.1042/bsr20100136 · Cited by 337
Melani, C. C., Sangaletti, S., Barazzetta, F. M., Werb, Z., & Colombo, M. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1882 · Cited by 335
Self-citationExtracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics
Islam, M. S., Ciavattini, A., Petraglia, F., Castellucci, M., & Ciarmela, P. (2017) · Human Reproduction Update · doi:10.1093/humupd/dmx032 · Cited by 329
Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases
Park, C. G., Hartl, C., Schmid, D., Carmona, E. M., Kim, H., & Goldberg, M. S. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar1916 · Cited by 326
“A given drug can exhibit differential efficacy depending on the degree of tumor progression at which the drug is administered (36).”
BackgroundChen, T. T., Luque, A., Lee, S., Anderson, S. M., Segura, T., & Iruela‐Arispe, M. L. (2010) · The Journal of Cell Biology · doi:10.1083/jcb.200906044 · Cited by 332
Impaired Infarct Healing in Atherosclerotic Mice With Ly-6ChiMonocytosis
Panizzi, P. R., Świrski, F. K., Figueiredo, J., Waterman, P. R., Sosnovik, D. E., Aïkawa, E., Libby, P., Pittet, M. J., Weissleder, R., & Nahrendorf, M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.08.089 · Cited by 327
Roles of Matrix Metalloproteinases in Tumor Metastasis and Angiogenesis
Yoon, S.-O., Park, S.-J., Yun, C.-H., & Chung, A. (2003) · BMB Reports · doi:10.5483/bmbrep.2003.36.1.128 · Cited by 320
Stromal biology of pancreatic cancer
Chu, G. C., Kimmelman, A. C., Hezel, A. F., & DePinho, R. A. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21209 · Cited by 330
Belotti, D., Paganoni, P., Manenti, L., Garofalo, A., Marchini, S., Taraboletti, G., & Giavazzi, R. (2003) · PubMed · Cited by 317
An IL-1 Cytokine Member, IL-33, Induces Human Basophil Activation via Its ST2 Receptor
Suzukawa, M., Iikura, M., Koketsu, R., Nagase, H., Tamura, C., Komiya, A., Nakae, S., Matsushima, K., Ohta, K., Yamamoto, K., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.5981 · Cited by 316
Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo
Brantley, D. M., Cheng, N., Thompson, E. J., Lin, Q. F., Brekken, R. A., Thorpe, P. E., Muraoka, R. S., Cerretti, D. P., Pozzi, A., Jackson, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205679 · Cited by 314
Self-citationThe Role of Tumor-Associated Neutrophils in Colorectal Cancer
Mizuno, R., Kawada, K., Itatani, Y., Ogawa, R., Kiyasu, Y., & Sakai, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030529 · Cited by 316
“In various murine models, TAMs and TANs are major sources of MMP9 [49], which promotes angiogenesis by its extracellular matrix-degrading properties [50].”
BackgroundTumor-associated neutrophils and neutrophil-targeted cancer therapies
Que, H., Fu, Q., Lan, T., Tian, X., & Wei, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188762 · Cited by 324
Extracellular regulation of VEGF: Isoforms, proteolysis, and vascular patterning
Vempati, P., Popel, A. S., & Gabhann, F. M. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.11.002 · Cited by 319
“Similarly, protease inhibitors have been shown to both decrease angiogenic sprouting (86) and increase sprouting (13).”
BackgroundInfluentialThe role of VEGF in the regulation of physiological and pathological angiogenesis
Ferrara, N. (2005) · Birkhäuser Basel eBooks · doi:10.1007/3-7643-7311-3_15 · Cited by 322
Matrix metalloproteinases in cancer
Itoh, Y., & Nagase, H. (2002) · Essays in Biochemistry · doi:10.1042/bse0380021 · Cited by 312
The other side of MMPs: Protective roles in tumor progression
Martin, M. D., & Matrisian, L. M. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9089-4 · Cited by 316
Heparanase as mediator of angiogenesis: mode of action
Elkin, M., Ilan, N., Ishai-Michaeli, R., Friedmann, Y., Papo, O., Pecker, I., & Vlodavsky, I. (2001) · The FASEB Journal · doi:10.1096/fj.00-0895fje · Cited by 311
Cysteine cathepsin proteases as pharmacological targets in cancer
Palermo, C., & Joyce, J. A. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.10.011 · Cited by 321
Angiogenic Role of LYVE-1–Positive Macrophages in Adipose Tissue
Cho, C.-H., Jun Koh, Y., Han, J., Sung, H.-K., Jong Lee, H., Morisada, T., Schwendener, R. A., Brekken, R. A., Kang, G., Oike, Y., et al. (2007) · Circulation Research · doi:10.1161/01.res.0000259564.92792.93 · Cited by 309
Self-citationStromal Cells in the Tumor Microenvironment
Denton, A. E., Roberts, E. W., & Fearon, D. T. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-78127-3_6 · Cited by 311
Metalloproteinases and their inhibitors in tumor angiogenesis
Handsley, M. M., & Edwards, D. R. (2005) · International Journal of Cancer · doi:10.1002/ijc.20945 · Cited by 311
Glioblastoma at the crossroads: current understanding and future therapeutic horizons
Singh, S., Dey, D., Barik, D., Mohapatra, I., Kim, S., Sharma, M., Prasad, S., Wang, P., Singh, A. R., & Singh, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02299-4 · Cited by 373
“209,210 Targeting these angiogenic pathways offers potential therapeutic avenues, with combination therapies addressing VEGF resistance through simultaneous inhibition of complementary pathways.”
Müller-Hermelink, N., Braumüller, H., Pichler, B., Wieder, T., Mailhammer, R., Schaak, K., Ghoreschi, K., Yazdi, A., Haubner, R., Sander, C. A., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.04.001 · Cited by 302
Deryugina, E. I., Zając, E., Juncker‐Jensen, A., Kupriyanova, T. A., Welter, L. M., & Quigley, J. P. (2014) · Neoplasia · doi:10.1016/j.neo.2014.08.013 · Cited by 310
“Discussion Although high levels of neutrophils and macrophages have been previously associated with tumor angiogenesis and malignant progression in cancer patients [13–15,45–47], xenograft models [10,37,38,48,49], and genetic models of cancer [23,32,33,50], a quantitative investigation of TAM versus TAN contribution t…”
BackgroundKim, Y. J., Kim, H. K., Cho, H. H., Bae, Y. C., Suh, K. T., & Jung, J. S. (2007) · Cellular Physiology and Biochemistry · doi:10.1159/000110447 · Cited by 298
Cancer invasion and metastasis: changing views
Duffy, M. J., McGowan, P. M., & Gallagher, W. M. (2007) · The Journal of Pathology · doi:10.1002/path.2282 · Cited by 303
The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma
Fields, G. B. (2019) · Cells · doi:10.3390/cells8090984 · Cited by 304
Matrix metalloproteinases: old dogs with new tricks.
Somerville, R. P. T., Oblander, S. A., & Apte, S. (2003) · Genome biology · doi:10.1186/gb-2003-4-6-216 · Cited by 303
Matrix metalloproteinases in tumorigenesis: an evolving paradigm
Hua, H., Li, M., Luo, T. L., Yin, Y., & Jiang, Y. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0763-x · Cited by 304
50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches
Suggitt, M., & Bibby, M. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.971.11.3 · Cited by 304
The regulation of MMP targeting to invadopodia during cancer metastasis
Jacob, A., & Prekeris, R. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00004 · Cited by 312
“Additionally, cancer cells have lesser capability to colonize the lungs of MMP2 or MMP9 deficient mice compared to wild type mice (Itoh et al., 1998, 1999) and cancer cell proliferation is decreased in tumors obtained from MMP9 knock-out mice (Bergers et al., 2000; Coussens et al., 2000).”
BackgroundBekes, E. M., Schweighofer, B., Kupriyanova, T. A., Zając, E., Ardi, V. C., Quigley, J. P., & Deryugina, E. I. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.05.031 · Cited by 312
ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway
Zhang, Q., Lu, S.-H., Li, T., Yu, L., Zhang, Y., Zeng, H., Qian, X., Bi, J., & Lin, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1156-5 · Cited by 300
Adhami, V. M., Siddiqui, I. A., Ahmad, N., Gupta, S., & Mukhtar, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2840 · Cited by 296
Conditional mouse models of sporadic cancer
Jonkers, J., & Berns, A. J. M. (2002) · Nature reviews. Cancer · doi:10.1038/nrc777 · Cited by 299
Lakka, S. S., Gondi, C. S., Yanamandra, N., Olivero, W. C., Dinh, D. H., Gujrati, M., & Rao, J. S. (2004) · Oncogene · doi:10.1038/sj.onc.1207616 · Cited by 297
RetractedPorkka, K., Laakkonen, P. M., Hoffman, J. A., Bernasconi, M., & Ruoslahti, E. I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.062189599 · Cited by 292
Cathepsin S Controls Angiogenesis and Tumor Growth via Matrix-derived Angiogenic Factors
Wang, B., Sun, J., Kitamoto, S., Yang, M., GRUBB, A. O., Chapman, H. A., Kalluri, R., & Shi, G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509134200 · Cited by 295
den Steen, P. E. V., Wuyts, A., Husson, S. J., Proost, P., Damme, J. V., & Opdenakker, G. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03760.x · Cited by 293
Regulation of angiogenesis by extracellular matrix
Sottile, J. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2003.07.002 · Cited by 291
SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion
Kitamura, T., Kometani, K., Hashida, H., Matsunaga, A., Miyoshi, H., Hosogi, H., Aoki, M., Oshima, M., Hattori, M., Takabayashi, A., et al. (2007) · Nature Genetics · doi:10.1038/ng1997 · Cited by 288
Cancer metastasis: Mechanisms of inhibition by melatonin
Su, S., Hsieh, M., Yang, W., Chung, W., Reiter, R. J., & Yang, S. (2016) · Journal of Pineal Research · doi:10.1111/jpi.12370 · Cited by 292
Zhou, X., Yan, T., Huang, C., Xu, Z., Wang, L., Jiang, E., Wang, H., Yang, C., Liu, K., Shao, Z., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0911-3 · Cited by 287
Prudova, A., Keller, U. A. D., Butler, G. S., & Overall, C. M. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m000050-mcp201 · Cited by 291
Fernández, C. A., Li, Y., Louis, G. W., Yang, J., Kutok, J. L., & Moses, M. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2391 · Cited by 283
Breast cancer metastasis to the bone: mechanisms of bone loss
Chen, Y., Sosnoski, D. M., & Mastro, A. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2781 · Cited by 283
MATRIX METALLOPROTEINASE-2 (MMP-2) AND MMP-9 IN PULMONARY PATHOLOGY
Chakrabarti, S., & Patel, K. D. (2005) · Experimental Lung Research · doi:10.1080/019021490944232 · Cited by 281
MMPs as therapeutic targets—Still a viable option?
Fingleton, B. (2007) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2007.06.006 · Cited by 284
Neutrophils Promote the Malignant Glioma Phenotype through S100A4
Liang, J., Piao, Y., Holmes, L., Fuller, G. N., Henry, V. K., Tiao, N., & de Groot, J. F. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1279 · Cited by 277
“Although activated myeloid cells such as M2-skewed macrophages can directly secrete proangiogenic factors (36-39), tumor associated neutrophils may also regulate tumor angiogenesis in an indirect way, such as through shifting stem cells towards a mesenchymal phenotype.”
Brantley‐Sieders, D. M., Zhuang, G., Hicks, D. J., Fang, W. B., Hwang, Y., Cates, J., Coffman, K. T., Jackson, D., Bruckheimer, E., Muraoka-Cook, R. S., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33154 · Cited by 283
Phospholipase D Signaling Pathways and Phosphatidic Acid as Therapeutic Targets in Cancer
Bruntz, R. C., Lindsley, C. W., & Brown, H. A. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.009217 · Cited by 286
“Latent forms of VEGF can be sequestered in the ECM and become bioavailable after proteolytic processing by proteases, such as MMP9 (Bergers et al., 2000; Kessenbrock et al., 2010).”
BackgroundAngiogenesis, Vasculogenesis, and Induction of Healing in Chronic Wounds
Bauer, S. M., Bauer, R. J., & Velazquez, O. C. (2005) · Vascular and Endovascular Surgery · doi:10.1177/153857440503900401 · Cited by 274
Matrix metalloproteinases: roles in cancer and metastasis
Fingleton, B. (2006) · Frontiers in bioscience · doi:10.2741/1811 · Cited by 272
Moss, L. A. S., Jensen-Taubman, S., & Stetler‐Stevenson, W. G. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.08.044 · Cited by 276
Lopez, T., & Hanahan, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00055-7 · Cited by 268
Self-citationAngiogenesis by Implantation of Peripheral Blood Mononuclear Cells and Platelets Into Ischemic Limbs
Iba, O., Matsubara, H., Nozawa, Y., Fujiyama, S., Amano, K., Mori, Y., Kojima, H., & Iwasaka, T. (2002) · Circulation · doi:10.1161/01.cir.0000031332.45480.79 · Cited by 268
RetractedIntracranial aneurysms: links among inflammation, hemodynamics and vascular remodeling
Hashimoto, T. N., Meng, H., & Young, W. L. (2006) · Neurological Research · doi:10.1179/016164106x14973 · Cited by 267
Iohara, K., Zheng, L. W., Wake, H., Ito, M., Nabekura, J., Wakita, H., Nakamura, H., Into, T., Matsushita, K., & Nakashima, M. (2008) · Stem Cells · doi:10.1634/stemcells.2008-0393 · Cited by 266
ADAMTS1/METH1 Inhibits Endothelial Cell Proliferation by Direct Binding and Sequestration of VEGF165
Luque, A., Carpizo, D. R., & Iruela‐Arispe, M. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212964200 · Cited by 265
The Effect of Matrix Density on the Regulation of 3-D Capillary Morphogenesis
Ghajar, C. M., Chen, X., Harris, J. W., Suresh, V., Hughes, C. C. W., Jeon, N. L., Putnam, A. J., & George, S. C. (2007) · Biophysical Journal · doi:10.1529/biophysj.107.120774 · Cited by 263
VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
You, W., Sennino, B., Williamson, C. W., Falcón, B. L., Hashizume, H., Yao, L., Aftab, D. T., & McDonald, D. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2527 · Cited by 262
Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone
Pratap, J., Lian, J. B., Javed, A., Barnes, G. B., van Wijnen, A. J., Stein, J. L., & Stein, G. S. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9032-0 · Cited by 264
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
Reiss, K. A., Angelos, M. G., Dees, E. C., Yuan, Y., Ueno, N. T., Pohlmann, P. R., Johnson, M. L., Chao, J., Shestova, O. E., Serody, J. S., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03495-z · Cited by 268
Zając, E., Schweighofer, B., Kupriyanova, T. A., Juncker‐Jensen, A., Minder, P., Quigley, J. P., & Deryugina, E. I. (2013) · Blood · doi:10.1182/blood-2013-05-501494 · Cited by 268
“In Mmp9-null hosts, a lack of proMMP-9 expression prevents the angiogenic switch and significantly reduces angiogenesis and metastasis.(16,18) Similarly, biochemical inhibition of overall MMP-9 activity also severely reduced levels of angiogenesis.”
BackgroundSounni, N. E., Devy, L., Hajitou, A., Frankenne, F., Munaut, C., Gilles, C., Deroanne, C., Thompson, E. W., Foidart, J. M., & Noël, A. (2002) · The FASEB Journal · doi:10.1096/fj.01-0790com · Cited by 259
Zuo, J., Zhu, W., Li, M., Li, X., Yi, H. L., Zeng, G., Wan, X., He, Q., Li, J., Qu, J., et al. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23175 · Cited by 258
Tang, Y., Kesavan, P., Nakada, M. T., & Li, Y. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.73.2.2 · Cited by 257
El-Kenawi, A., & El‐Remessy, A. B. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12344 · Cited by 261
“Matrix degrading and remodelling-targeted therapy Matrix degrading and remodelling are activated by tumours to modify local micro-environment, which in turn promote their angiogenic potential (Bergers et al., 2000; Vlodavsky and Friedmann, 2001).”
BackgroundMolecular basis of endothelial cell morphogenesis in three‐dimensional extracellular matrices
Davis, G. E., Bayless, K. J., & Mavila, A. (2002) · The Anatomical Record · doi:10.1002/ar.10159 · Cited by 247
Mast cells are an essential hematopoietic component for polyp development
Gounaris, E. G., Erdman, S. E., Restaino, C. R., Gurish, M. F., Friend, D. S., Gounari, F., Lee, D. M., Zhang, G., Glickman, J. N., Shin, K., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704620104 · Cited by 254
The history of the angiogenic switch concept
Ribatti, D., Nico, B., Crivellato, E., Roccaro, A. M., & Vacca, A. (2006) · Leukemia · doi:10.1038/sj.leu.2404402 · Cited by 250
Sbardella, D., Fasciglione, G. F., Gioia, M., Ciaccio, C., Tundo, G. R., Marini, S., & Coletta, M. (2011) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.10.015 · Cited by 251
The Inflammatory Tumor Microenvironment and Its Impact on Cancer Development
de Visser, K. E., & Coussens, L. M. (2006) · KARGER eBooks · doi:10.1159/000092969 · Cited by 250
Protease-Activated Drug Development
Choi, K. Y., Swierczewska, M., Lee, S., & Chen, X. S. (2012) · Theranostics · doi:10.7150/thno.4068 · Cited by 253
Lafleur, M. A., Handsley, M. M., Knäuper, V., Murphy, G., & Edwards, D. R. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.17.3427 · Cited by 248
Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development
Hojilla, C. V., Mohammed, F. F., & Khokha, R. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601327 · Cited by 244
Monitoring Response to Anticancer Therapy by Targeting Microbubbles to Tumor Vasculature
Korpanty, G. J., Carbon, J. G., Grayburn, P. A., Fleming, J. B., & Brekken, R. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1313 · Cited by 244
Self-citationGenetically Engineered Models Have Advantages over Xenografts for Preclinical Studies
Becher, O. J., & Holland, E. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3827 · Cited by 244
Harrod, C. G., Bendok, B. R., & Batjer, H. H. (2005) · Neurosurgery · doi:10.1227/01.neu.0000156644.45384.92 · Cited by 244
The Use of Targeted Mouse Models for Preclinical Testing of Novel Cancer Therapeutics
Olive, K. P., & Tuveson, D. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0436 · Cited by 244
Riau, A. K., Beuerman, R. W., Lim, L. S., & Mehta, J. S. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.09.034 · Cited by 245
Mosig, R., Dowling, O., DiFeo, A. V., Ramirez, M. C. M., Parker, I. C., Abe, E., Diouri, J., Aqeel, A. A., Wylie, J. D., Oblander, S. A., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm060 · Cited by 240
Cell death, therapeutics, and the immune response in cancer
Hänggi, K., & Ruffell, B. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.02.001 · Cited by 255
Zcharia, E., Metzger, S., Chajek‐Shaul, T., Aingorn, H., Elkin, M., Friedmann, Y., Weinstein, T., Li, J.-P., Lindahl, U., & Vlodavsky, I. (2004) · The FASEB Journal · doi:10.1096/fj.03-0572com · Cited by 246
Matrix metalloproteinases at cancer tumor–host interface
Noël, A., JOST, M., & Maquoi, E. (2007) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2007.05.011 · Cited by 240
Gene expression profiling of cutaneous wound healing
Deonarine, K., Panelli, M. C., Stashower, M. E., Jin, P., Smith, K., Slade, H. B., Norwood, C., Wang, E., Marincola, F. M., & Stroncek, D. F. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-11 · Cited by 229
Deryugina, E. I., & Quigley, J. P. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2009.09.017 · Cited by 239
Matrix Metalloproteinases in Bone Resorption, Remodeling, and Repair
Paiva, K. B. S., & Granjeiro, J. M. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.05.001 · Cited by 245
Understanding the role of tissue degrading enzymes and their inhibitors in development and disease
Cawston, T. E., & Wilson, A. (2006) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2006.06.007 · Cited by 241
Neutrophil extracellular traps in cancer progression
Cools‐Lartigue, J., Spicer, J. D., Najmeh, S., & Ferri, L. E. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1683-3 · Cited by 240
“phils at a later time point (11 weeks of age) did not alter tumor number or size [39].”
BackgroundMethodInfluentialJodele, S., Blavier, L., Yoon, J. M., & DeClerck, Y. A. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-7887-8 · Cited by 231
Molecular mechanisms and therapeutic target of NETosis in diseases
Huang, J., Hong, W., Wan, M., & Zheng, L. (2022) · MedComm · doi:10.1002/mco2.162 · Cited by 252
Metadata
- Authors
- Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., & Hanahan, D.
- Affiliations
- University of California, San Francisco (US)
- Hope Heart Institute (US)
- Kyoto University (JP)
- Harold C. Simmons Comprehensive Cancer Center (US)
- RIKEN Center for Brain Science (JP)
- Corresponding author
- Hanahan, Douglas
- Venue
- Nature Cell Biology
- Published
- 2000-09-20
- Volume
- 2
- Issue
- 10
- Pages
- 737-744
- ISSN
- 1465-7392 (ISSN-L)
- 1476-4679
- PMC
- PMC2852586
- OpenAlex
- W1574172480
- Cited by
- 2,797
- References
- 45
- Citations by year
- 2026: 37 · 2025: 55 · 2024: 76 · 2023: 74 · 2022: 96 · 2021: 90 · 2020: 92 · 2019: 88 · 2018: 82 · 2017: 107 · 2016: 110 · 2015: 98 · 2014: 133 · 2013: 140 · 2012: 137
- FWCI
- 36.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P01CA072006, R01CA057621)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- MMP-9, angiogenic switch, vascular endothelial growth factor, VEGF signaling, MMP-2, urokinase, tumor angiogenesis, tumor growth, matrix metalloproteinase inhibitors, SU5416, transgenic mice
- MeSH terms
- Acetamides, Animals, Cell Transformation, Neoplastic, Genes, Switch, Islets of Langerhans, Lymphokines, Mice, Transgenic, Neovascularization, Pathologic, Pancreatic Neoplasms, Tissue Distribution, Signal Transduction, Endothelial Growth Factors, Receptors, Growth Factor, Matrix Metalloproteinase 9, Receptor Protein-Tyrosine Kinases, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
